ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Policlinico Universitario Agostino Gemelli at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Policlinico Universitario Agostino Gemelli takes part in 22 sessions at ESMO 2026 in Madrid. Its program spans several cancer types, with particular attention to gynaecological cancers and treatment decisions. Topics include ovarian and endometrial cancer therapies, including results from trials of treatments for recurrent ovarian cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Policlinico Universitario Agostino Gemelli Rome, Italy | |
Research and teaching hospital of the Catholic University of the Sacred Heart in Rome, Italy. | Satellite Fri Oct 23 09:45–11:15 MSD - Emerging Evidence and Treatment Integration in Ovarian and Endometrial Cancer Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 10:53–11:08 Emerging targeted approaches in endometrial cancer and future clinical integration Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 11:13–11:15 Closing Gynaecological cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Baseline 18F-FDG PET/CT volumetric parameters identify patients at risk of early clinical failure in R/M HNSCC treated with ICIs Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Clinical and molecular predictors of outcome in resected and metastatic GIST: A real-world cohort Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 EC_ItaLynch: Mainstreaming genetic testing for Lynch syndrome in endometrial cancer Gynaecological cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: An independent real-world analysis Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced/recurrent endometrial cancer (EC): Biomarker analysis from ENGOT-en9/LEAP-001 Gynaecological cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Incidence and patterns of co-occurrence of targetable genomic alterations in metastatic Prostate Cancer (mPC): Implications for personalized treatment stratification Genitourinary cancersBiomarkers & precision oncology Abstract Fri Oct 23 16:42–16:47 Chair Sat Oct 24 08:30–10:00 Rapid oral 2: Gynaecological cancers Gynaecological cancers Abstract Sat Oct 24 08:52–08:57 Abstract Sat Oct 24 09:02–09:14 Invited Discussant LBA41 and 1248RO Gynaecological cancers Poster Sat Oct 24 12:00–12:45 Chair Sat Oct 24 14:45–16:15 Abstract Sat Oct 24 14:50–14:55 Abstract Sat Oct 24 15:49–16:01 Abstract Sun Oct 25 08:50–09:00 Poster Sun Oct 25 12:00–12:45 Satellite Sun Oct 25 13:05–13:15 Building Bridges in the Management of CSCC Melanoma & skin cancers Satellite Sun Oct 25 13:15–13:35 Resectable or Not: Navigating the Gray Zones in Advanced CSCC Melanoma & skin cancers Satellite Sun Oct 25 13:35–13:50 Defining High-risk CSCC: Identifying Patients Who Need More Melanoma & skin cancers Satellite Sun Oct 25 13:50–14:20 Timing and Selection of Systemic Therapy in Resectable CSCC Melanoma & skin cancers Satellite Sun Oct 25 14:20–14:30 Audience Q&A Melanoma & skin cancers Satellite Sun Oct 25 18:30–20:00 MSD - Is the precision medicine ecosystem ready? Overcoming diagnostic barriers in oncology Biomarkers & precision oncology Satellite Sun Oct 25 18:30–18:40 Opening Keynote - The evolution of precision oncology: Science vs the implementation gap Biomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 A proteo-energetic transcriptomic signature and mitochondrial-associated genes identify poor-prognosis in ovarian cancer Gynaecological cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Niraparib first-line maintenance in optimally debulked ovarian cancer patients: Genomic alterations and survival by molecular status Gynaecological cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Second primary malignancies in patients with GIST: Clinical and molecular correlates in a real-world cohort Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology |
Find decision makers at Policlinico Universitario Agostino Gemelli
Tell us what you sell and we’ll find the people at Policlinico Universitario Agostino Gemelli most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction